Local tumor heating plus immune stimulants to boost checkpoint therapy for metastatic pancreatic cancer
Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors
This approach uses a targeted tumor-heating treatment together with immune-stimulating drugs to help people with advanced pancreatic cancer get a stronger response to immune checkpoint therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma NIH-funded |
| Lab location | 1 site (Norman, United States) |
| Project ID | NIH-11294281 on NIH RePORTER |
What this research studies
If I join, doctors will heat and destroy part of my pancreatic tumor with a focused photothermal treatment, then inject immune-stimulating medicine directly into the treated area while giving standard immune checkpoint drugs systemically. The local heating is meant to release tumor antigens and, together with the injected stimulants, turn the tumor into a kind of vaccine that attracts and activates T cells. The team will follow tumor size at treated and distant sites, measure immune activity, and track side effects to see how my body responds. This builds on lab work and early human experience but needs larger clinical testing to confirm benefits and safety.
Who could benefit from this research
Good fit: Adults with unresectable or metastatic pancreatic cancer who are eligible for immune checkpoint therapy and can tolerate a local ablation procedure and clinic visits would be the ideal candidates.
Not a fit: People with early-stage resectable pancreatic cancer, those who cannot undergo local ablation or immunotherapy, or tumors not reachable for localized treatment are less likely to benefit.
Why it matters
Potential benefit: If successful, this could make immunotherapy work better for people with metastatic pancreatic cancer by generating stronger, body-wide anti-tumor immune responses.
How similar studies have performed: Preclinical studies and small early clinical experiences combining local photothermal ablation with immune stimulants have shown elimination of treated tumors and some control of distant metastases, but larger human trials remain limited.
Where this research is happening
Norman, United States
- University of Oklahoma — Norman, United States (Active)
Researchers
- Principal investigator: Chen, Wei R. — University of Oklahoma
- Study coordinator: Chen, Wei R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.